HRP20180061T1 - Indolkarbonitrili kao selektivni modulatori androgenskih receptora - Google Patents
Indolkarbonitrili kao selektivni modulatori androgenskih receptora Download PDFInfo
- Publication number
- HRP20180061T1 HRP20180061T1 HRP20180061TT HRP20180061T HRP20180061T1 HR P20180061 T1 HRP20180061 T1 HR P20180061T1 HR P20180061T T HRP20180061T T HR P20180061TT HR P20180061 T HRP20180061 T HR P20180061T HR P20180061 T1 HRP20180061 T1 HR P20180061T1
- Authority
- HR
- Croatia
- Prior art keywords
- intended
- compound according
- muscle wasting
- compound
- wasting associated
- Prior art date
Links
- 239000000849 selective androgen receptor modulator Substances 0.000 title 1
- 150000001875 compounds Chemical class 0.000 claims 11
- 206010028289 Muscle atrophy Diseases 0.000 claims 6
- 201000000585 muscular atrophy Diseases 0.000 claims 6
- 206010007558 Cardiac failure chronic Diseases 0.000 claims 4
- 208000020832 chronic kidney disease Diseases 0.000 claims 4
- 230000035876 healing Effects 0.000 claims 4
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 206010020100 Hip fracture Diseases 0.000 claims 2
- 206010046543 Urinary incontinence Diseases 0.000 claims 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 2
- 208000035475 disorder Diseases 0.000 claims 2
- 239000000825 pharmaceutical preparation Substances 0.000 claims 2
- SKDVMPZQJMZEAC-SECBINFHSA-N 1-[(2r)-1-methylsulfonylpropan-2-yl]-4-(trifluoromethyl)indole-5-carbonitrile Chemical group N#CC1=CC=C2N([C@@H](CS(C)(=O)=O)C)C=CC2=C1C(F)(F)F SKDVMPZQJMZEAC-SECBINFHSA-N 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 229940124597 therapeutic agent Drugs 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- C07D209/24—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals with an alkyl or cycloalkyl radical attached to the ring nitrogen atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/404—Indoles, e.g. pindolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/06—Anabolic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
- A61P5/26—Androgens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/08—Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/30—Indoles; Hydrogenated indoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to carbon atoms of the hetero ring
- C07D209/42—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Claims (14)
1. Spoj
[image]
,
naznačen time što je (R)-1-(1-(metilsulfonil)propan-2-il)-4-(trifluormetil)-1H-indol-5-karbonitril.
2. Enantiomerno obogaćena smjesa, naznačena time što sadrži spoj u skladu s patentnim zahtjevom 1.
3. Spoj u skladu s patentnim zahtjevom 1, naznačen time što je u kristalnom obliku.
4. Spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, naznačen time što je namijenjen upotrebi kao aktivna terapijska tvar.
5. Spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, naznačen time što je namijenjen upotrebi u liječenju poremećaja koji se bira između gubitka mišića povezanog s kroničnom opstruktivnom plućnom bolešću (COPD), gubitka mišića povezanog s kroničnom bolešću bubrega (CKD), gubitka mišića povezanog s kroničnom srčanom insuficijencijom (CHF), te inkontinencije mokraće.
6. Spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, naznačen time što je namijenjen upotrebi u ubrzavanju popravka i zacjeljivanja prijeloma kuka.
7. Spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, naznačen time što je namijenjen upotrebi u ubrzavanju zacjeljivanja opeklina.
8. Farmaceutski pripravak, naznačen time što sadrži spoj u skladu s patentnim zahtjevom 1 do patentnog zahtjeva 3, kao i jednu ili više farmaceutski prihvatljivih pomoćnih tvari.
9. Farmaceutski pripravak u skladu s patentnim zahtjevom 8, naznačen time što navedeni pripravak sadrži 0,1-50 mg spoja.
10. Spoj namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 5 do 7, naznačen time što se primjenjuje 0,1-50 mg spoja.
11. Spoj u skladu s bilo kojim od patentnih zahtjeva 1 do 3, naznačen time što je u kombinaciji s drugim terapijskim sredstvom.
12. Kombinacija u skladu s patentnim zahtjevom 11, naznačena time što je namijenjena upotrebi u liječenju poremećaja koji se bira između gubitka mišića povezanog s kroničnom opstruktivnom plućnom bolešću (COPD), gubitka mišića povezanog s kroničnom bolešću bubrega (CKD), gubitka mišića povezanog s kroničnom srčanom insuficijencijom (CHF), te inkontinencije mokraće.
13. Kombinacija u skladu s patentnim zahtjevom 12, naznačena time što je namijenjena upotrebi u ubrzavanju popravka i zacjeljivanja prijeloma kuka.
14. Kombinacija u skladu s patentnim zahtjevom 12, naznačena time što je namijenjena upotrebi u ubrzavanju zacjeljivanja opeklina.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261672455P | 2012-07-17 | 2012-07-17 | |
| US201361748874P | 2013-01-04 | 2013-01-04 | |
| PCT/IB2013/001530 WO2014013309A1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
| EP13758975.0A EP2875013B1 (en) | 2012-07-17 | 2013-07-15 | Indolecarbonitriles as selective androgen receptor modulators |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20180061T1 true HRP20180061T1 (hr) | 2018-02-23 |
Family
ID=49117887
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20180061TT HRP20180061T1 (hr) | 2012-07-17 | 2018-01-15 | Indolkarbonitrili kao selektivni modulatori androgenskih receptora |
Country Status (39)
| Country | Link |
|---|---|
| US (5) | US8957104B2 (hr) |
| EP (1) | EP2875013B1 (hr) |
| JP (1) | JP6106746B2 (hr) |
| KR (1) | KR102127939B1 (hr) |
| CN (1) | CN104619693B (hr) |
| AR (1) | AR091770A1 (hr) |
| AU (1) | AU2013291721B2 (hr) |
| BR (1) | BR112015000940B1 (hr) |
| CA (1) | CA2879104C (hr) |
| CL (1) | CL2015000119A1 (hr) |
| CO (1) | CO7240378A2 (hr) |
| CR (1) | CR20150008A (hr) |
| CY (1) | CY1120064T1 (hr) |
| DK (1) | DK2875013T3 (hr) |
| DO (1) | DOP2015000004A (hr) |
| EA (1) | EA026371B8 (hr) |
| ES (1) | ES2657912T3 (hr) |
| HK (1) | HK1208867A1 (hr) |
| HR (1) | HRP20180061T1 (hr) |
| HU (1) | HUE036238T2 (hr) |
| IL (1) | IL236448A (hr) |
| IN (1) | IN2014KN02993A (hr) |
| JO (1) | JO3384B1 (hr) |
| LT (1) | LT2875013T (hr) |
| ME (1) | ME02996B (hr) |
| MX (1) | MX349943B (hr) |
| MY (2) | MY173845A (hr) |
| NZ (1) | NZ703129A (hr) |
| PE (1) | PE20150371A1 (hr) |
| PH (1) | PH12015500104A1 (hr) |
| PL (1) | PL2875013T3 (hr) |
| PT (1) | PT2875013T (hr) |
| RS (1) | RS56810B1 (hr) |
| SG (1) | SG11201408493WA (hr) |
| SI (1) | SI2875013T1 (hr) |
| TW (1) | TWI574946B (hr) |
| UY (1) | UY34911A (hr) |
| WO (1) | WO2014013309A1 (hr) |
| ZA (1) | ZA201500096B (hr) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10155099B2 (en) | 2009-09-21 | 2018-12-18 | Cook Regentec Llc | Method for infusing stem cells |
| MY173845A (en) * | 2012-07-17 | 2020-02-24 | Glaxosmithkline Ip No 2 Ltd | Indolecarbonitriles as selective androgen receptor modulators |
| EP3097077A1 (en) | 2014-01-21 | 2016-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
| CA2964371A1 (en) * | 2014-10-16 | 2016-04-21 | Gtx, Inc. | Methods of treating urological disorders using sarms |
| CN105130872B (zh) * | 2015-08-25 | 2018-01-30 | 江西师范大学 | 一种3位三氟甲基取代吲哚的制备方法 |
| CN110437125B (zh) * | 2019-09-06 | 2021-03-12 | 苏州旺山旺水生物医药有限公司 | 一种Tezacaftor中间体II的制备方法 |
| US20220306609A1 (en) * | 2021-03-23 | 2022-09-29 | Nido Biosciences, Inc. | Bicyclic compounds as androgen receptor modulators |
| CN115010574B (zh) * | 2022-06-06 | 2024-01-05 | 爱斯特（成都）生物制药股份有限公司 | 1-溴-2-氯-4-氟-2碘苯的合成方法 |
Family Cites Families (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK12742000A3 (sk) | 1998-02-25 | 2001-05-10 | Genetics Institute, Inc. | Inhibítory fosfolipázových enzýmov, farmaceutický prostriedok s ich obsahom a ich použitie |
| KR100415791B1 (ko) * | 1998-06-19 | 2004-01-24 | 화이자 프로덕츠 인코포레이티드 | 피롤로[2,3-디]피리미딘 화합물 |
| US6576265B1 (en) | 1999-12-22 | 2003-06-10 | Acell, Inc. | Tissue regenerative composition, method of making, and method of use thereof |
| ES2471240T3 (es) | 2002-05-24 | 2014-06-25 | Bayer Cropscience Ag | Procedimiento de preparación de derivados de tioalquilamina |
| US7517899B2 (en) * | 2004-03-30 | 2009-04-14 | Wyeth | Phenylaminopropanol derivatives and methods of their use |
| CN1960973A (zh) * | 2004-03-30 | 2007-05-09 | 惠氏公司 | 作为去甲肾上腺素(ne)与血清素(5－h t)活性和单胺重摄取的调控剂以治疗血管舒缩症状(vms)的1－(1h－吲哚－1－基)－3－(4－甲基哌嗪－1－基)－1－苯基丙烷－2－醇衍生物和相关化合物 |
| CN102091068B (zh) | 2004-05-03 | 2012-09-19 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂(sarms)的吲哚、苯并呋喃和苯并噻吩衍生物 |
| CN1980934B (zh) | 2004-05-03 | 2011-10-26 | 詹森药业有限公司 | 作为选择性雄激素受体调节剂（sarms）的新的吲哚衍生物 |
| AU2005243240B2 (en) | 2004-05-03 | 2012-03-15 | Janssen Pharmaceutica N.V. | Novel indole derivatives as selective androgen receptor modulators (SARMS) |
| AU2005250116B2 (en) * | 2004-06-01 | 2011-01-20 | F. Hoffmann-La Roche Ag | 3-amino-1-arylpropyl indoles as monoamine reuptake inhibitor |
| US8232394B2 (en) * | 2005-07-29 | 2012-07-31 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine derivatives; their intermediates and synthesis |
| GB0526246D0 (en) * | 2005-12-22 | 2006-02-01 | Novartis Ag | Organic compounds |
| BRPI0709612A2 (pt) * | 2006-03-15 | 2011-07-19 | Wyeth Corp | composto de fórmula i; método para o tratamento de um distúrbio no sistema nervoso central relacionado ou afetado pelo receptor histamina-3 em um paciente que necessita deste tratamento; método para a inibição do receptor h3; composição farmacêutica; e processo para a preparação de um composto de fórmula i |
| CN101426778A (zh) * | 2006-03-15 | 2009-05-06 | 惠氏公司 | 作为组胺-3拮抗剂的n-经取代-氮杂环基胺 |
| EP2079466B1 (en) * | 2006-09-29 | 2014-01-15 | GlaxoSmithKline LLC | Substituted indole compounds |
| RU2493157C2 (ru) * | 2008-08-20 | 2013-09-20 | Пфайзер Инк. | ПРОИЗВОДНЫЕ ПИРРОЛО[2,3-d]ПИРИМИДИНА |
| WO2010118287A1 (en) * | 2009-04-10 | 2010-10-14 | Radius Health, Inc. | Selective androgen receptor modulators |
| CN102574860A (zh) * | 2009-10-15 | 2012-07-11 | 辉瑞大药厂 | 吡咯并[2,3-d]嘧啶化合物 |
| CA2782720A1 (en) * | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| WO2012006419A2 (en) | 2010-07-07 | 2012-01-12 | Board Of Regents Of The University Of Texas System | Pro-neurogenic compounds |
| RU2598842C2 (ru) * | 2011-01-20 | 2016-09-27 | Мерк Шарп Энд Домэ Корп. | Антагонисты рецептора минералокортикоидов |
| AU2012357296B2 (en) * | 2011-12-21 | 2017-04-13 | Jiangsu Hengrui Medicine Co., Ltd. | Pyrrole six-membered heteroaryl ring derivative, preparation method therefor, and medicinal uses thereof |
| MY173845A (en) * | 2012-07-17 | 2020-02-24 | Glaxosmithkline Ip No 2 Ltd | Indolecarbonitriles as selective androgen receptor modulators |
| EP3097077A1 (en) * | 2014-01-21 | 2016-11-30 | Glaxosmithkline Intellectual Property (No. 2) Limited | Crystalline forms of (r)-1 -(1-(methylsulfonyl)propan-2-yl)-4-(trifluoromethyl)indoline-5-carbonitrile |
-
2013
- 2013-07-15 MY MYPI2015000121A patent/MY173845A/en unknown
- 2013-07-15 RS RS20180119A patent/RS56810B1/sr unknown
- 2013-07-15 SG SG11201408493WA patent/SG11201408493WA/en unknown
- 2013-07-15 LT LTEP13758975.0T patent/LT2875013T/lt unknown
- 2013-07-15 AR ARP130102513A patent/AR091770A1/es active IP Right Grant
- 2013-07-15 PE PE2015000039A patent/PE20150371A1/es active IP Right Grant
- 2013-07-15 US US13/941,911 patent/US8957104B2/en active Active
- 2013-07-15 DK DK13758975.0T patent/DK2875013T3/en active
- 2013-07-15 HU HUE13758975A patent/HUE036238T2/hu unknown
- 2013-07-15 SI SI201330945T patent/SI2875013T1/en unknown
- 2013-07-15 JP JP2015522180A patent/JP6106746B2/ja active Active
- 2013-07-15 IN IN2993KON2014 patent/IN2014KN02993A/en unknown
- 2013-07-15 NZ NZ703129A patent/NZ703129A/en unknown
- 2013-07-15 UY UY0001034911A patent/UY34911A/es not_active Application Discontinuation
- 2013-07-15 AU AU2013291721A patent/AU2013291721B2/en active Active
- 2013-07-15 PT PT137589750T patent/PT2875013T/pt unknown
- 2013-07-15 ME MEP-2018-16A patent/ME02996B/me unknown
- 2013-07-15 CA CA2879104A patent/CA2879104C/en active Active
- 2013-07-15 JO JOP/2013/0214A patent/JO3384B1/ar active
- 2013-07-15 CN CN201380048232.8A patent/CN104619693B/zh active Active
- 2013-07-15 EA EA201492237A patent/EA026371B8/ru not_active IP Right Cessation
- 2013-07-15 BR BR112015000940-9A patent/BR112015000940B1/pt active IP Right Grant
- 2013-07-15 EP EP13758975.0A patent/EP2875013B1/en active Active
- 2013-07-15 MY MYPI2018001949A patent/MY198512A/en unknown
- 2013-07-15 PL PL13758975T patent/PL2875013T3/pl unknown
- 2013-07-15 MX MX2015000825A patent/MX349943B/es active IP Right Grant
- 2013-07-15 WO PCT/IB2013/001530 patent/WO2014013309A1/en active Application Filing
- 2013-07-15 KR KR1020157003959A patent/KR102127939B1/ko active IP Right Grant
- 2013-07-15 ES ES13758975.0T patent/ES2657912T3/es active Active
- 2013-07-15 TW TW102125297A patent/TWI574946B/zh active
-
2014
- 2014-11-20 US US14/549,034 patent/US9533948B2/en active Active
- 2014-12-23 CO CO14282153A patent/CO7240378A2/es unknown
- 2014-12-25 IL IL236448A patent/IL236448A/en active IP Right Grant
-
2015
- 2015-01-07 ZA ZA2015/00096A patent/ZA201500096B/en unknown
- 2015-01-08 DO DO2015000004A patent/DOP2015000004A/es unknown
- 2015-01-09 CR CR20150008A patent/CR20150008A/es unknown
- 2015-01-14 PH PH12015500104A patent/PH12015500104A1/en unknown
- 2015-01-16 CL CL2015000119A patent/CL2015000119A1/es unknown
- 2015-09-30 HK HK15109640.8A patent/HK1208867A1/xx unknown
-
2016
- 2016-11-22 US US15/358,458 patent/US10196353B2/en active Active
-
2018
- 2018-01-15 HR HRP20180061TT patent/HRP20180061T1/hr unknown
- 2018-02-13 CY CY20181100173T patent/CY1120064T1/el unknown
- 2018-12-20 US US16/226,763 patent/US10710963B2/en active Active
-
2020
- 2020-05-12 US US16/872,949 patent/US11299457B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20180061T1 (hr) | Indolkarbonitrili kao selektivni modulatori androgenskih receptora | |
| JP2015522603A5 (hr) | ||
| EA200901155A1 (ru) | Модуляторы фармакокинетических свойств терапевтических препаратов (варианты) и их использование в терапии | |
| MX2016006053A (es) | Compuestos selectivos de peptido yy (pyy) y usos de los mismos. | |
| BRPI1011220A2 (pt) | composição farmacêutica, métodos para tratar uma doença ou distúrbio, para administração respiratória de dois ou mais agentes ativos, para administração respiratória de uma combinação de agentes ativos, e, para preparar uma composição adequada. | |
| HRP20151443T1 (hr) | Terapijsko sredstvo protiv stenoze kralježniäśnog kanala | |
| ME02414B (me) | Tretman kronove bolesti lakvinimodom | |
| JP2010522242A5 (hr) | ||
| WO2015095772A3 (en) | Formulations and methods for targeted ocular delivery of therapeutic agents | |
| MY187047A (en) | Selective pyy compounds and uses thereof | |
| EA201491285A1 (ru) | Улучшенные композиции и способы доставки омепразола и ацетилсалициловой кислоты | |
| MD4539B1 (ro) | 4-Fenilpiridine substituite pentru tratamentul bolilor asociate cu receptorul NK-1 | |
| JP2015038135A5 (hr) | ||
| MA37455A1 (fr) | Utilisation d'un dérivé de pyrazole dans le traitement d'exacerbations aigues d'une maladie pulmonaire obstructive chronique | |
| JP2015524444A5 (hr) | ||
| JP2013231087A5 (hr) | ||
| MX2021010359A (es) | Una composicion farmaceutica para reducir la grasa localizada y sus usos. | |
| JP2017222722A5 (hr) | ||
| WO2011119227A3 (en) | Compositions for the treatment of central nervous system disorders including depression employing novel drug combination therapy to reduce suicidality in patients | |
| WO2009004995A1 (ja) | 生理活性物質を定着および発現させる方法 | |
| JP2013541583A5 (hr) | ||
| JP2009505991A5 (hr) | ||
| MY151230A (en) | Novel method | |
| WO2013026558A3 (de) | Kombinationstherapeutikum | |
| JP2007119497A5 (hr) |